AELIX Therapeutics is focused on developing a novel therapeutic vaccine aimed at curing HIV infection, utilizing a unique immunogen known as HTI. This immunogen was discovered by Dr. Christian Brander and is designed to enhance T-cell responses to specific regions of the HIV virus that are associated with better control of the infection. The HTI immunogen consolidates these beneficial regions into a single sequence, informed by extensive immune data from nearly 1,000 individuals living with HIV across various global cohorts. This data-driven approach ensures that the immunogen is tailored to effectively target the most vulnerable parts of the virus, thereby increasing the potential for a successful immune response.

The company has initiated several clinical trials to evaluate the safety, tolerability, and immunogenicity of the HTI vaccine. The first trial, AELIX-002, began in September 2017 and involves a heterologous prime-boost vaccination regimen using DNA plasmids and Modified-Virus-Ankara (MVA) vectors. AELIX-003, the second trial, is a collaboration with Gilead Sciences and aims to assess the vaccine's efficacy in conjunction with a TLR-7 agonist. Both trials include an analytical treatment interruption phase to evaluate participants' ability to control viral replication without antiretroviral therapy. The innovative design of the HTI immunogen, combined with rigorous clinical testing, positions AELIX Therapeutics at the forefront of HIV vaccine research.

Spain

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

AELIX Therapeutics

Company Details